Quisinostat (JNJ-26481585) 2HCl

Catalog No.S1096

Quisinostat (JNJ-26481585) 2HCl Chemical Structure

Molecular Weight(MW): 467.39

Quisinostat (JNJ-26481585) 2HCl is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2.

Size Price Stock Quantity  
In DMSO USD 330 In stock
USD 210 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 21 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Quisinostat (JNJ-26481585) 2HCl is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2.
Features An orally bioavailable, second-generation, hydroxamic acid-based HDAC inhibitor.
Targets
HDAC1 [1]
(Cell-free assay)		 HDAC2 [1]
(Cell-free assay)		 HDAC11 [1]
(Cell-free assay)		 HDAC10 [1]
(Cell-free assay)		 HDAC4 [1]
(Cell-free assay)
0.11 nM 0.33 nM 0.37 nM 0.46 nM 0.64 nM
In vitro

JNJ-26481585 exhibits broad spectrum antiproliferative activity in solid and hematologic cancer cell lines, such as all lung, breast, colon, prostate, brain, and ovarian tumor cell lines, with IC50 ranging from 3.1-246 nM, which is more potent than vorinostat, R306465, panobinostat, CRA-24781, or mocetinostat in various human cancer cell lines tested. [1] A recent study shows that JNJ-26481585 promotes myeloma cell death at low nanomolar concentrations by resulting in Mcl-1 depletion and Hsp72 induction. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HuT78 MknhSpVv[3Srb36gZZN{[Xl? MkH6NVAhdk1? MlT4bY5kemWjc3XzJJRp\SCuZY\lcEBw\iCjY3X0fYxifGWmIHz5d4lv\SCNMUCgc4YhcGm|dH;u[UBJOw>? NIHaS|A{ODBzMkSxPC=>
HepG2 M1rlWGNmdGxidnnhZoltcXS7IHHzd4F6 M2PFTFUtKDFyLDCyNEwhPDBuIEiwMEAyPjBiYX7kJFMzOCCwTR?= NFnCNWkzPCxiNEisJFczKGh? MUHUbIUhUUN3MDD2ZYx2\XNib3[gZ4VtdHNiZn;yJJF2cXOrbn;zeIF1KHS{ZXH0cYVvfCCjdDC0PEBidmRiN{KgbEB4\XKnIEixMlIh[W6mIEOwMlghdk1uIILld5Bm[3SrdnXsfU4> M3TLOVI5QDR7MEiw
RD cells NV\zfnNPTnWwY4Tpc44h[XO|YYm= NVzh[2pqOTVibl2= M4PGR|I1KGhiYX7kJFMxKGh? MkjIS3NMPjlyIHHu[EBLVkpvMk[0PFE2QDViY3;vdIVz[XSnZDD0c{BqdmS3Y3WgZ4xm[X[jZ3Wgc4YhfGinIHnubZRq[XSxcjDjZZNx[XOnLUmgbY51dyCrdIOgZYN1cX[nIICzOUBidmRicEO3JIZz[WevZX70d{BidmRib3[geIhmKGWoZnXjeI9zKGOjc4Dhd4UuOyCrboTvJIl1eyCjY4TpeoUheDF{IHHu[EBxOTdiZoLh[41mdnS| NI[2RWkzQDZzN{S0NS=>
RH30 cells MYLGeY5kfGmxbjDhd5NigQ>? M3LUeFE2KG6P MVWyOEBpKGGwZDCzNEBp M{HsSmdUUzZ7MDDhcoQhUk6MLUK2OFgyPTh3IHPvc5BmemG2ZXSgeI8hcW6mdXPlJINt\WG4YXflJI9nKHSqZTDpcol1cWG2b4KgZ4F{eGG|ZT25JIlvfG9iaYTzJIFkfGm4ZTDwN|Uh[W6mIICzO{BnemGpbXXueJMh[W6mIH;mJJRp\SCnZn\lZ5RweiClYYPwZZNmNTNiaX70c{BqfHNiYXP0bZZmKHBzMjDhcoQheDF5IH\yZYdu\W62cx?= MV2yPFYyPzR2MR?=
A549 cells NXHjXotWS2WubDD2bYFjcWyrdImgZZN{[Xl? MUOyOEwhPDhuIH;yJFczKGh? MVP0bIUhUUN3MDD2ZYx2\XNib3[gZ4VtdHNiZn;yJFQ5KGGwZDC3NkBpKG:oIIH1bZNqdm:|dHH0JJRz\WG2bXXueEB4\XKnIEiyMlQh[W6mIESyMlAhdk1uIILld5Bm[3SrdnXsfU4> MVmyO|QzOzR3NB?=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
HDAC1 / HDAC2 / HDAC4; 

PubMed: 30443188     


The effects of quisinostat on the expressions of HDACs in HCC cells. The expression levels of HDAC1, HDAC2 and HDAC4 were suppressed in both HCCLM3 and SMMC-7721 cell lines. Images were photographed with confocal microscope under ×200 magnification. Scale bar, 100 μm. Data were shown as mean ± SD. n = 3; * P < 0.05, ** P < 0.01 and *** P < 0.001 compared with DMSO group.

p21 / CDK2 / CDK4 / CDK6 / Cyclin D1 / Cyclin E1 / Cyclin A2; 

PubMed: 30443188     


Western blot analysis of p21, cdk2, cdk4, cdk6, cyclinD1, cyclinE1 and cyclinA2 proteins after quisinostat treatment. 

Caspase-3/ Cleaved caspase-3 / caspase-9 / Cleaved caspase-9 / PARP / Cleaved PARP / Bcl-xl / Bcl2 / Bax / Survivin; 

PubMed: 30443188     


Western blot analysis of Caspase-3, cleaved-Caspase-3, Caspase-9, cleaved-Caspase-9, PARP, cleaved-PARP, Bcl-xl, Bcl2, Bax and survivin protein were carried out after quisinostat treatment. 

PI3K-p110 / PI3K-p85 / p-AKT / JNK / p-JNK / p-c-Jun ; 

PubMed: 30443188     


HCCLM3 and SMMC-7721 cells were treated with quisinostat (12.5, 25.0 and 50.0nM) for 48 h. Western blot analysis was used to evaluate expressions of PI3K-p110, PI3K-p85, phosphorylation of AKT473, JNK, phosphorylation of JNK and c-Jun.

30443188
Growth inhibition assay
Cell viability; 

PubMed: 30443188     


Quisinostat inhibited cell proliferation in HCCLM3, Sk-hep-1, Hep-3B, Huh7 and SMMC-7721 cells as a concentration-dependent manner verified by CCK8 assay. 

30443188
In vivo In an HDAC1-responsive A2780 ovarian tumor screening model, JNJ-26481585 dosing at its maximal tolerated dose (10 mg/kg i.p. and 40 mg/kg p.o.) for 3 days leads to an HDAC1-regulated fluorescence , which predicts tumor growth inhibition. Furthermore, JNJ-26481585 also shows more potent inhibitory effects on the growth of C170HM2 colorectal liver metastases than 5-fluorouracil/Leucovorin. [1]

Protocol

Kinase Assay:[1]
- Collapse

HDAC activity assays :

In all cases, full-length HDAC proteins are expressed using baculovirus-infected Sf9 cells. In addition, HDAC3 is coexpressed as a complex with human NCOR2. For assessing activity of HDAC1-containing cellular complexes, immunoprecipitated HDAC1 complexes are incubated with an [3H]acetyl- labeled fragment of histone H4 peptide [biotin-(6-aminohexanoic)Gly-Ala-(acetyl[3H])Lys-Arg-His-Arg-Lys-Val-NH2] in a total volume of 50μL enzyme assay buffer (25mM HEPES (pH 7.4), 1 M sucrose, 0.1 mg/mL BSA and 0.01% (v/v) Triton X-100). Incubation is performed for 45 minutes at 37 °C (immunoprecipitates) or 30 min at room temperature. Before addition of substrate, HDAC inhibitors are added at increasing concentrations and preincubated for 10 minutes at room temperature. After incubation, the reaction is quenched with 35μL stop buffer (1 M HCl and 0.4 M acetic acid). Released [3H]acetic acid is extracted with 800μL ethyl acetate and quantified by scintillation counting. Equal amounts of HDAC1 are immunoprecipitated as indicated by Western blot analysis. HDAC1 activity results are presented as mean ± SD of three independent experiments on a single lysate.
Cell Research:Cell proliferation assays
- Collapse
  • Cell lines: NCL-H2106, Colo699 and LNCAP cells
  • Concentrations: 0-300 nM
  • Incubation Time: 24 hours
  • Method: All cell lines are obtained from American Type Culture Collection and cultured according to instructions. The effect of HDAC inhibitors on cell proliferation is measured using an MTT. Proliferation of non–small cell lung carcinoma (NSCLC) cell lines is assessed using an Alamar Blue–based assay. For proliferation of hematologic cell lines, cells are incubated for 72 hours and the cytotoxic activity is evaluated by MTS assay. Data are presented as mean IC50 or IC40 ± SD of at least three independent experiments.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: HCT116 human colon carcinoma cells are injected s.c. into the inguinal region of athymic male NMRI nu/nu mice, C170HM2 cell suspensions are injected into the peritoneal cavity of male MFI nude mice.
  • Formulation: JNJ-26481585 is formulated at 2 mg/mL in 20% hydroxypropyl-β-cyclodextrin (final pH 8.7).
  • Dosages: ≤10 mg/kg
  • Administration: Administered via both p.o. and i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 79 mg/mL (169.02 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 467.39
Formula

C21H28Cl2N6O2
CAS No. 875320-31-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was thinking of resuspending the powder in 10% hydroxy-propyl-β-cyclodextrin, 25mg/ml mannitol, in sterile water (final pH 8.7). Is this a good vehicle to use? What is the solubility of this chemical in such a vehicle?

  • Answer:

    This vehicle can be used for in vivo studies. The following papers also used this vehicle: 1. http://www.nature.com/leu/journal/v23/n10/full/leu2009121a.html; 2. http://cancerres.aacrjournals.org/content/69/13/5307.long (The solvent contains 10% hydroxypropyl-β-cyclodextrin, 0.8% HCl (0.1 N), 0.9 % NaOH (0.1 N), 3.4% mannitol and pyrogen-free water). The solubility is 2mg/ml.

selleck catalog

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

  • LMK-235 New

    LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.

  • CAY10603 New

    CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.

  • Domatinostat (4SC-202,Domatinostat) New

    4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.

  • Panobinostat (LBH589)

    Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

  • Entinostat (MS-275)

    Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

  • Trichostatin A (TSA)

    Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

  • RGFP966

    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.

  • Tubastatin A

    Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).

Tags: buy Quisinostat (JNJ-26481585) 2HCl | Quisinostat (JNJ-26481585) 2HCl supplier | purchase Quisinostat (JNJ-26481585) 2HCl | Quisinostat (JNJ-26481585) 2HCl cost | Quisinostat (JNJ-26481585) 2HCl manufacturer | order Quisinostat (JNJ-26481585) 2HCl | Quisinostat (JNJ-26481585) 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID